Leading the AI transformation at NewYork-Presbyterian, one of the world's largest medical networks.
ET
Will AI Make Us Healthier?
Will AI Make Us Healthier?
Inside a Top Hospital’s Journey to Modernize Healthcare
Every industry has a breaking point. For healthcare, it arrived long before the artificial intelligence boom. Growing patient backlogs, systemic workforce burnout, and ballooning operational costs have pushed modern hospital infrastructure to its absolute limit. Historically, the framework for medical leadership has been centered on damage control by efficiently managing wait times, rationing bed counts, and balancing rigid budgets.
We are now in a different moment entirely.
Artificial intelligence is a fundamental paradigm shift that demands an entirely new way of thinking about human data, institutional scale, and standards of care. The healthcare organizations, investors, and entrepreneurs that survive the upcoming decade will be those that realize the era of reactive medicine is over.
Dr. Peter Fleischut and Dr. Pierre Elias are currently executing this exact transformation playbook at NewYork-Presbyterian one of the world's largest medical networks. As Chief Transformation and Growth Officer, Dr. Fleischut has led a highly successful and an aggressive strategy managing over 120 active AI initiatives. He is spearheading a massive digital overhaul across multiple hospitals to eliminate clinical friction and accelerate the delivery of modern care.
Dr. Pierre Elias is the Medical Director for AI and a principal investigator at the CRADLE deep learning lab, where his team builds clinical tools designed to augment decision-making and expand clinical insight.
As one example, their collaboration has turned the world’s most basic, low-cost tests into unprecedented predictive shields. Using their recently FDA-cleared model, EchoNext, they have successfully trained algorithms to analyze a standard 10-second EKG and uncover hidden structural heart diseases that are otherwise imperceptible during routine reviews. By catching complex cardiac deterioration before a patient ever shows a single symptom, they are successfully demonstrating how to convert theory into practice with a massive impact on health outcomes.
In this session we will discuss the operational framework, funding models, and institutional agility needed to deploy and scale AI and innovation across millions of patients responsibly.
Submit your questions for Dr. Peter Fleischut and Dr. Pierre Elias for a chance to ask them live.
Every industry has a breaking point. For healthcare, it arrived long before the artificial intelligence boom. Growing patient backlogs, systemic workforce burnout, and ballooning operational costs have pushed modern hospital infrastructure to its absolute limit. Historically, the framework for medical leadership has been centered on damage control by efficiently managing wait times, rationing bed counts, and balancing rigid budgets.
We are now in a different moment entirely.
Artificial intelligence is a fundamental paradigm shift that demands an entirely new way of thinking about human data, institutional scale, and standards of care. The healthcare organizations, investors, and entrepreneurs that survive the upcoming decade will be those that realize the era of reactive medicine is over.
Dr. Peter Fleischut and Dr. Pierre Elias are currently executing this exact transformation playbook at NewYork-Presbyterian one of the world's largest medical networks. As Chief Transformation and Growth Officer, Dr. Fleischut has led a highly successful and an aggressive strategy managing over 120 active AI initiatives. He is spearheading a massive digital overhaul across multiple hospitals to eliminate clinical friction and accelerate the delivery of modern care.
Dr. Pierre Elias is the Medical Director for AI and a principal investigator at the CRADLE deep learning lab, where his team builds clinical tools designed to augment decision-making and expand clinical insight.
As one example, their collaboration has turned the world’s most basic, low-cost tests into unprecedented predictive shields. Using their recently FDA-cleared model, EchoNext, they have successfully trained algorithms to analyze a standard 10-second EKG and uncover hidden structural heart diseases that are otherwise imperceptible during routine reviews. By catching complex cardiac deterioration before a patient ever shows a single symptom, they are successfully demonstrating how to convert theory into practice with a massive impact on health outcomes.
In this session we will discuss the operational framework, funding models, and institutional agility needed to deploy and scale AI and innovation across millions of patients responsibly.
Submit your questions for Dr. Peter Fleischut and Dr. Pierre Elias for a chance to ask them live.
